Oncoinvent will present operational and financial update for the first half of
2025 on Wednesday 27 August 2025 at 08:00am (CET). The presentation will be live
streamed in English followed by a Q&A session. The presentation is available on
https://channel.royalcast.com/landingpage/hegnarmedia/20250827_3/ (https://eur03.
safelinks.protection.outlook.com/?url=https%3A%2F%2Fchannel.royalcast.com%2Flandi
ngpage%2Fhegnarmedia%2F20250827_3%2F&data=05%7C02%7Ckvam%40oncoinvent.com%7C5f4c9
2e2cb894c93f5e608ddbd38a461%7C6da5bf1fbdf44dbb949301c5dcdde30e%7C0%7C0%7C63887477
3164979877%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIl
AiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=tEYWc9MJbDhLNsi
Iclt%2FzRkFjrhxVQlbbMlR1nVakAM%3D&reserved=0).
The interim financial report for the first half 2025 and the presentation
material will be published at 07:00 am (CET) and will also be available on
https://www.oncoinvent.com/investors/reports-and-presentation/
About Oncoinvent
Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases post-surgery, harnessing the benefits of modern
radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical
development program in two indications. In addition to a recently finalized
phase 1/2a trial in colorectal cancer, Oncoinvent is running two trials in
ovarian cancer: one phase 1 trial and one randomized phase 2 trial in the US, UK
and Europe. Preliminary clinical efficacy data are highly encouraging, and no
serious toxicity or safety concerns have been reported to date. The Oncoinvent
team consists runs a state-of-the-art manufacturing facility to produce drug
products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the
Euronext Growth Oslo.
About Radspherin
Radspherin® is an investigational radiopharmaceutical designed for the local
treatment of cancer that has spread to body cavities. It consists of billions of
calcium carbonate microparticles containing the radioactive material radium-224.
The mode of action is the decay of radium-224 emitting alpha-particles, a highly
potent form of ionizing radiation. Radspherin® is investigated in ongoing
clinical studies to treat peritoneal carcinomatoses from ovarian and colorectal
cancer and it is administered intraperitoneally after surgical resection with
removal of all macroscopic tumors.
Forward-Looking Statements
All statements other than statements of historical facts contained in this press
release are forward-looking statements and are not a representation that
Oncoinvent's plans, estimates, or expectations will be achieved. These forward
-looking statements represent Oncoinvent's expectations as of the date of this
press release, and Oncoinvent disclaims any obligation to update the forward
-looking statements. These forward-looking statements are subject to known and
unknown risks and uncertainties that may cause actual results to differ
materially, including with respect to whether the results of clinical or other
studies will support the use of our product offerings, the impact of results of
such studies, our expectations of the reliability, accuracy and performance of
our tests, or of the benefits of our tests and product offerings to patients,
providers and payers.
For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com
Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com